Frontiers in Drug Development
September 5, 2019
Explore the potential of AI in minimising inefficiencies and uncertainty in drug discovery, design and development.
February 13, 2020
It is high time to rethink and improve preclinical testing to pave the way to optimise First in Human Studies.
Subscribe to our ECPM Newsletter to keep informed about upcoming courses and seminars
sAVE THE dATES
June 25, 2020
September 10, 2020
February 4, 2021
June 24, 2021
FRontiers in Drug Development: Outline
ECPM offers one day seminars on current topics, new trends and developments in drug development science. These seminars provide the opportunity to integrate work and further education, to discuss with experts face-to-face and to build an international network. They take place back to back to the ECPM modules and build a compulsory part of the ECPM course. Additionally they are open to our alumni and other interested scientists and can be booked separately.
Participants should learn more about various topic such as:
Future trends in drug development including Future Information Technologies, Nano-Technologies, Computer Simulation and Modelling, Personalised Medicine, Genomics, Biologicals and Biosimilars, Advanced Therapeutics.
Regulatory Agency updates from FDA, EMA and Swissmedic.
Ethical, Economic and Epidemiological Considerations and Concepts in Drug Development.
1 day workshops, recognised for continuing professional development. The workshops are held on day four of each ECPM Course Module.
5 workshops over a period of two years equal 1 ECTS credit.
Accredited as continuing education by the Swiss Society of Pharmaceutical Medicine (SGPM) and the Swiss Society of Pharmaceutical Professionals (SwAPP).
For MMD participants, the fee of this Module is not included in the MMD tuition fee.
For use à la carte or CPD, course fee incl. Course material, lunch and coffee breaks is CHF 680. For Alumni, SGPM and SwAPP members CHF 580, for academia a reduced price of CHF 210 is offered.
List of Seminars since 1991
ECPM/FDA Workshop, 1992 and 1994
Computer Simulation and Modelling, 1996
The EMEA and You, 1997
Evidence-based Medicine, 1997
Active Drug Metabolites and Stereoisomers, 1998
Future Information Technologies, 1998
Streamlining Proof of Principle, 1999
Genomics in Pharmaceutical Medicine, 2000
Enhanced and Frontloaded Decision Making, 2000
Perspectives of Knowledge Management, 2001
Pharmaceutical Specialist Education Models, 2002
Optimising Swiss Drug Development & Regulation in 2002, 2002
EUFEPS/ECPM Conference on Optimising Drug Development: Getting the Dose Right, 2002
Update on European and American Drug Regulation, 2003
Medicines, Moral and Money - Economic and Legal Issues in Drug Development and Marketing, 2003
EUFEPS/ECPM Conference on Optimising Drug Development: Integrating New Concepts and Tools, 2003
Personalised Medicine, 2004
Swiss Drug Development Today, 2004
Quality Cardiovascular Drug Development, 2004
EUFEPS/ECPM Conference on Optimising Drug Development: Balancing Safety and Effectiveness from Discovery to Clinical Practice, 2004
European Drug Regulation, Promotion and Law, 2005
The Latest on Biologicals and Biosimilars, 2006
Swiss Drug Development and Legal Regulation 2006, 2006
Personalised Medicines – A Reality Check, 2006
Incentivising Better Medicines for Children, 2007
Pharma and Biotech Industries Scenarios 2020, 2007
Vaccines – From Prevention to Therapy, 2008
Clinical Endpoints & Outcomes, 2008
Advanced Therapeutics – From Nano to Stem Cells, 2008
Specifics of Devices and Combination Products, 2009
The Risk-Benefit Value Equation, 2009
Frontiers of Medicines Development, 2010
The Price of Globalisation: Drug Trials in Resource-Limited Settings, 2010
Elderly in Future Pharmacotherapy, 2010
Emerging Definitions of Risk Management, 2011
20th Anniversary of ECPM: Medicines’ Development in the Next Decade of the Human Genome Project, 2011
Biomarkers in Drug Development, 2012
Off-Label Drug Use, 2012
Genes, Nutrition and Disease, 2012
Incentivising Better Medicines for Children, 2013
Update in Pharmacovigilance and Drug Safety, 2013
Health Technology Assessment – Today and Tomorrow, 2013
Finding the right dose – From Paracelsus to Pharmacometrics, 2014
Targeting the Right Endpoint with the Right Trial Design in the Right Patient, 2014
Why do Clinical Trials Fail? – Pre-Clinical, Clinical, and Post-Marketing Issues, 2014
Sharing and Exchanging health Data Online, 2015
International Health System and Market Access, 2015
Measuring Health: Epidemiology and Burden of Disease, 2015
Genomics in Drug Development and Beyond, 2016
Key Concepts in Clinical Trial Design, 2016
Big Data, Patients and the Real World in Pharmaceutical Medicine and Drug Development, 2016
Pharmaceutical and Regulatory Law, 2017
Health Care Systems & Pharma Market Access, 2017
Translational Medicine in Drug Development Roles and Models - where do they fit?, 2017
One Dose Fits All - Versus Tailor-Made Dosing, 2018
Impact and Challenges of Advanced Therapy Medicinal Products, 2018
Big Data and Artificial Intelligence in Healthcare and Drug Development, 2018
Global Streamlining of Marketing Authorisation, 2019
How to Master the Final Hurdle of Drug Development; 2019